“Monoclonal antibodies will soon arrive that can be administered subcutaneously and in many cases it will be possible to intervene at the patient’s home without having to hospitalize him and clog the emergency rooms or medical areas of hospitals”. This was stated by Giorgio Palù, president of AIFA, in the hearing in the Constitutional Affairs Commission of the Senate, on the Ddl conversion of decree-law number 172 on vaccination obligations and strengthening of Covid-19 green certifications. These second generation antibodies “will always be administered within 72 hours of the onset of the disease”, recalled Palù.
“For two anti-Covid antivirals, Merck’s molnupiravir (MSD outside the US and Canada) and Pfizer’s Paxlovid,” we received the dossier. The FDA has authorized them and EMA is evaluating them. , but it will be important to study the dossier. For one of the two drugs the efficacy is somewhat decreased by admission of the manufacturer compared to the beginning “, said the president of Aifa.
#Covid #Palù #Aifa #Monoclonal #antibodies #home